Psychedelics, once notorious for their recreational use and cultural impact during the 1960s, are now the subject of renewed scientific interest due to their potential therapeutic benefits. This article explores the classification of psychedelics, their mechanisms of action, therapeutic applications, and the legal and ethical considerations surrounding their use.

Psychedelics can be broadly classified into several groups based on their chemical structure and mechanism of action:

• Classic Psychedelics: Such as LSD (lysergic acid diethylamide), psilocybin (found in magic mushrooms), and DMT (dimethyltryptamine). These substances primarily affect the serotonin receptors in the brain, particularly the 5-HT2A receptor, which plays a key role in regulating mood, cognition, and perception.
• Dissociative Drugs: Including ketamine and phencyclidine (PCP), which act mainly on NMDA receptors involved in memory and perception.
• Empathogens: Such as MDMA (ecstasy), which enhance emotional and social connectivity by increasing levels of serotonin, dopamine, and norepinephrine.

Psychedelics generally alter consciousness and perception by modulating neurotransmitter systems in the brain. For instance, classic psychedelics induce profound changes in visual and auditory perception, mood, and thought processes by stimulating serotonin receptors, thereby affecting various neural circuits that involve areas of the brain associated with emotion and sensory perception.

Recent clinical trials have demonstrated the potential of psychedelics to treat a variety of mental health disorders:

• Depression: Multiple studies have shown that psilocybin and LSD can produce significant and rapid antidepressant effects in patients with treatment-resistant depression (Carhart-Harris et al., 2016).
• Anxiety and PTSD: MDMA-assisted psychotherapy has been found effective in treating PTSD, while psilocybin has shown promise in reducing anxiety in terminal cancer patients (Mithoefer et al., 2018).
• Addiction: There is emerging evidence that psychedelics can help treat substance abuse disorders, including alcohol and nicotine dependence, by disrupting maladaptive patterns of behavior and thought (Bogenschutz et al., 2015).

While psychedelics are generally considered safe when taken in controlled environments, they can cause adverse effects such as nausea, dizziness, and disorientation. More severe risks include psychological distress and the exacerbation of pre-existing mental disorders. The set (individual’s mindset) and setting (environmental context) play crucial roles in influencing the outcomes of psychedelic experiences.

Psychedelics are generally considered physiologically safe and do not lead to dependence or addiction. Studies show that these substances have a low toxicity relative to dose, and serious adverse physical effects are rare. For example, research indicates that psilocybin has a low potential for toxicity and overdose (Johnson et al., 2018).

While physically safe for most healthy individuals, psychedelics can induce intense psychological experiences that can be challenging, particularly in unsupervised settings. The most significant risks include:

• Transient Anxiety and Paranoia: During a psychedelic experience, individuals may experience periods of intense anxiety and paranoia. These effects are typically temporary but can be distressing.
• Precipitation of Psychotic Episodes: There is evidence to suggest that psychedelics can trigger acute psychotic reactions, particularly in individuals predisposed to psychosis (Strassman, 1995).
• Hallucinogen Persisting Perception Disorder (HPPD): In rare cases, users may experience ongoing visual disturbances and perceptual changes after the initial effect of the drug has worn off (Litjens et al., 2014).

The concept of “set and setting” — a term that refers to the individual’s mindset and the physical and social environment in which the drug is taken — plays a critical role in the safety and outcomes of psychedelic use. Ensuring a supportive, controlled environment and the presence of trained personnel can significantly mitigate risks (Hartogsohn, 2017).

Screening for personal and family history of mental health issues can help reduce the risk of adverse psychological reactions. Ongoing monitoring by medical professionals during psychedelic sessions is also crucial to manage any acute reactions that may arise.

The legal status of psychedelics varies by country, with most listed as Schedule I drugs under international conventions, indicating a high potential for abuse and no accepted medical use. However, recent research findings have prompted some countries to reconsider these classifications. For example, the FDA (Food and Drug Administration) in the United States has granted Breakthrough Therapy designation to psilocybin for depression and MDMA for PTSD, reflecting their potential medical value and the need for further research.

The resurgence of interest in the therapeutic potential of psychedelics marks a significant shift in the perception of these once-stigmatised substances. While promising, the use of psychedelics in therapy requires careful consideration of the psychological and situational contexts to maximise benefits and minimise risks. Ongoing research and thoughtful integration into clinical practice are essential to fully realise their potential in mental health treatment.

• Bogenschutz, M. P., & Johnson, M. W. (2015). Classic hallucinogens in the treatment of addictions. Progress in Neuro-Psychopharmacology & Biological Psychiatry, 64, 250-258.
• Carhart-Harris, R. L., Bolstridge, M., Rucker, J., Day, C. M. J., Erritzoe, D., Kaelen, M., Bloomfield, M., Rickard, J. A., Forbes, B., Feilding, A., Taylor, D., Pilling, S., Curran, V. H., & Nutt, D. J. (2016). Psilocybin with psychological support for treatment-resistant depression: an open-label feasibility study. The Lancet Psychiatry, 3(7), 619-627.
• Mithoefer, M. C., Feduccia, A. A., Jerome, L., Mithoefer, A., Wagner, M., Walsh, Z., Hamilton, S., Yazar-Klosinski, B., Emerson, A., & Doblin, R. (2018). MDMA-assisted psychotherapy for treatment of PTSD: study protocol for a phase 3 trial. Psychopharmacology, 235(2), 273-283.
• Hartogsohn, I. (2017). Set and setting, psychedelics and the placebo response: An extra-pharmacological perspective on psychopharmacology. Journal of Psychopharmacology, 31(12), 1259-1267.
• Johnson, M. W., Richards, W. A., & Griffiths, R. R. (2018). Human hallucinogen research: guidelines for safety. Journal of Psychopharmacology, 22(6), 603-620.
• Litjens, G., Brunt, T. M., Alderliefste, G. J., & Westerink, R. H. (2014). Hallucinogen persisting perception disorder and the serotonergic system: a comprehensive review including new MDMA-related clinical cases. European Neuropsychopharmacology, 24(8), 1309-1323.
• Strassman, R. J. (1995). Hallucinogenic drugs in psychiatric research and treatment. Perspectives and prospects. Journal of Nervous and Mental Disease, 183(3), 127-138.

How to get in touch

If you or your patient/NDIS clients need immediate mental healthcare assistance, feel free to get in contact with us on 1800 NEAR ME – admin@therapynearme.com.au.